Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic Stem Cell Transplantation With Zoledronic Acid for Relapsed/Refractory Solid Tumors
NCT06625190Phase 2Recruiting
- Sponsor
- University of Florida
- Start
- Feb 2026
- Primary completion
- Feb 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zoledronic acid in solid tumor, sponsored by University of Florida. Primary endpoints: Disease-Free Survival at 1 year and Incidence of acute Graft-Versus-Host Disease at 2 years. Started Feb 2026; status: recruiting.
02
Drugs
zoledronic acid
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06625190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06625190.